Patents
Literature
2 results about "Binding selectivity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Binding selectivity is defined with respect to the binding of ligands to a substrate forming a complex. Binding selectivity describes how a ligand may bind more preferentially to one receptor than another. A selectivity coefficient is the equilibrium constant for the reaction of displacement by one ligand of another ligand in a complex with the substrate. Binding selectivity is of major importance in biochemistry and in chemical separation processes.
A benzisoselenazol derivative, its preparation method and application in preparing RNA fluorescent probe
This invention discloses a benzo[selenazole] derivative, its preparation method, and its application in the preparation of RNA fluorescent probes. The benzo[selenazole] derivative provided by this invention has the following structural formula: [structural formula would be inserted here]. This benzo[selenazole] derivative is a typical fluorescently activated probe, exhibiting excellent selective recognition and binding ability for RNA molecules. It demonstrates excellent resistance to biological background interference and exhibits high binding selectivity and recognition specificity for RNA in both live and fixed cell systems. It possesses advantages such as high signal-to-noise ratio and excellent fluorescence photostability, making it suitable for real-time, dynamic fluorescence imaging detection of intracellular RNA. It can achieve in-situ visualization and tracing of changes in subcellular RNA distribution and content. The synthesis method of the benzo[selenazole] derivative provided by this invention has a clear process flow, mild and stable reaction conditions, requires no demanding equipment or special reagents, and uses commercially available and readily available conventional chemicals as raw materials. The operation is simple and easy to perform, with strong overall process operability, making it suitable for large-scale production applications.
Owner:GUANGDONG UNIV OF TECH
Human fc variants having improved fcgamma-riia binding selectivity
PendingEP4421091A4Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody medical ingredientsBioinformaticsBinding selectivity
The present invention relates to Fc variants which have improved half-life by binding to and unbinding from FcRn in a pH-dependent manner and which have improved selective binding to Fcyreceptors. Novel human Fc domain variants of the present invention have lower capacity to bind to immune inhibiting receptor FcyRIIb and have higher capacity to bind to immune activating receptor FcyRIIa (increased A / I ratio) than a wild-type human antibody Fc domain and conventional antibodies approved as antibody therapeutic agents, thereby having remarkably improved ADCP induction ability and having maximized half-life in blood in which excellent pH-selective FcRn binding and unbinding capacity is exhibited, and thus bind to numerous peptide drug therapeutics having a low half-life and retention time in the body so as to enable the peptide drug therapeutics to have an increased blood half-life and exhibit long-term drug efficacy, and can maximize the immune mechanism of therapeutic protein drugs so as to be effectively used as an improved antibody drug.
Owner:KOREA UNIV RES & BUSINESS FOUND